This content is from: Premium
One of the Best-Performing Hedge Funds in Recent Years Just Got Richer
Why Avoro Capital Advisors cheered Gilead’s deal to acquire Immunomedics.
Talk about hitting the jackpot.Gilead Sciences’ deal to acquire Immunomedics for about $21 billion, or $88 per share, was a huge, unexpected windfall for several hedge funds after shares of Immunomedics nearly doubled to $86.84 on Monday following the announcement.At the end of the second quarter, the biopharma company’s stock
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.